key: cord-0862323-fyedyt07
authors: Ranard, Lauren S.; Parikh, Sahil A.; Kirtane, Ajay J.
title: COVID-19–Specific Strategies for the Treatment of ST-Segment Elevation Myocardial Infarction in China ∗
date: 2020-08-14
journal: Journal of the American College of Cardiology
DOI: 10.1016/j.jacc.2020.07.054
sha: ac291d397b5cc5a070362d4897ebc0b73d3633f5
doc_id: 862323
cord_uid: fyedyt07

[Figure: see text]

One of the greatest challenges of observational research is discerning the "effect" of the exposure of interest from underlying secular (or other) trends. So in a sense, this analysis is best used in descriptive terms, rather than as an attempt to ascribe causation to any one of the multiple moving parts (e.g., the evolution of the outbreak itself, the change in reperfusion protocol, or the regional differences in patterns of disease and care). In the pre-outbreak and outbreak periods in both Hubei and non-Hubei provinces, the proportion of cases with S-FMC #12 h was similar. However, the majority (w55%) of patients presenting with STEMI were categorized as "walk-in" patients and another w30% were "transfers." Even in the defined pre-outbreak period, PPCI was not offered to w20% of patients presenting with STEMI. While at first blush 20% of STEMI patients not receiving PPCI seems high, in comparison to prior studies from China, this represents substantial improvement over time (7) . Perhaps the overriding lesson from this analysis is the importance of reperfusion therapies for STEMI as a whole, with modifications based upon the specific care patterns within regional networks and systems, and individualized to the patient. 

Heart disease and stroke statistics-2020 update: a report from the

Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic

Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era

Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction care in Hong Kong

Clinical pathway for management of suspected or positive novel coronavirus-19 patients with ST segment elevation myocardial infarction

A nationwide study of STEMI treatment and prognosis in China during the COVID-19 pandemic

ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data

STsegment elevation in patients with COVID-19 -a case series

ST-elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes

Why fibrinolytic therapy for STEMI in the COVID-19 pandemic is not your new best friend

COVID-19, primary percutaneous coronary intervention, ST-segment elevation myocardial infarction, thrombolysis

2 0 : ---COVID-19-Specific STEMI Care in China